Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

4.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.8K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

9.3K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
9.3K
Drug Discovery: Overview01:26

Drug Discovery: Overview

8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Promotion of shade avoidance by BBX5 involves activation of PIF4 along with auxin biosynthetic and signaling genes.

PLoS genetics·2026
Same author

Structural basis and functional mining of active site loop for fine tuning substrate affinity of L-asparaginase from Bacillus licheniformis.

Journal of hazardous materials·2026
Same author

Evolutionary conservation and lineage-specific virulence repurposing of the core housekeeping gene ushA in Enterobacteriaceae.

Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases·2026
Same author

The transcription factors GmSTF1 and GmSTF2 promote photosynthesis and lignin biosynthesis in soybean.

aBIOTECH·2026
Same author

Interpretative diagnostic model for neuroblastoma metastases using bone marrow cytology.

Journal of translational medicine·2026
Same author

Constructing a Stabilized Interface in Ultra-High Nickel Single-Crystal LiNi<sub>0.90</sub>Co<sub>0.05</sub>Mn<sub>0.05</sub>O<sub>2</sub> by a Long-Time Molten-Salt Route.

Small methods·2026

Related Experiment Video

Updated: Sep 14, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

A highly annotated drug combination resource for catalyzing precision combinatorial therapy.

Tianyi You1, Lili Wang2, Jianhua Wang1

  • 1Department of Bioinformatics, Tianjin Key Laboratory of Inflammation Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.

Scientific Data
|July 23, 2025
PubMed
Summary
This summary is machine-generated.

A new database, OncoDrug+, offers comprehensive cancer drug combination data. It includes genetic evidence and targets, aiding oncologists in selecting effective, evidence-based combination therapies for patients.

More Related Videos

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.3K

Related Experiment Videos

Last Updated: Sep 14, 2025

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K
High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

12.0K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

12.3K

Area of Science:

  • Oncology
  • Pharmacology
  • Bioinformatics

Background:

  • Cancer drug combinations can overcome resistance and reduce toxicity.
  • Existing databases lack crucial contextual information for clinical application.
  • Oncologists need evidence-based data to match patients with optimal drug combinations.

Purpose of the Study:

  • To develop a comprehensive cancer drug combination database, OncoDrug+.
  • To integrate diverse evidence types for robust combination selection.
  • To facilitate evidence-based clinical decision-making for cancer therapies.

Main Methods:

  • Manual collection and integration of drug combination data from multiple sources.
  • Inclusion of data from FDA databases, clinical guidelines, trials, case reports, and models.
  • Development of a database with genetic evidence, pharmacological targets, and evidence scores.

Main Results:

  • OncoDrug+ contains 7895 data entries, covering 77 cancer types.
  • Includes 2201 unique drug combination therapies and 1200 biomarkers.
  • Provides detailed genetic and pharmacological information beyond simple response data.

Conclusions:

  • OncoDrug+ addresses the gap in existing drug combination databases.
  • Enables evidence-based application of cancer drug combinations in clinical settings.
  • Supports personalized cancer treatment strategies through integrated data.